Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTELLANCE 2 in recurrent EGFR-amplified glioblastoma
NL-OMON47561Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2015
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of depatuxizumab mafodotin in glioblastoma (GBM), sponsored by AbbVie Inc. Started Sep 2015; status: completed.
02
Drugs
depatuxizumab mafodotin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON47561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47561.